Rainbow Biosciences, the biotech subsidiary of Rainbow Coral Corp.
(OTCBB: RBCC), announced today that 3D cell culturing technology
developed by its joint venture partner Nano3D
BioSciences (n3D) was recently used in a breakthrough study using
Dr. Mikhail Kolonin, an associate professor at the University of Texas
Health Science Center at Houston, and Dr. Glauco Souza of n3D authored a
study that demonstrates how effective 3D cell culturing by magnetic
levitation is in generating white adipose tissue organoids, or
adiposphere. In a significant breakthrough, these 3D structures
presented vascular-like structures when pre-adpocyte stem cells were
co-cultured with endothelial cells.
The study, “Adipose
tissue engineering in three-dimensional levitation tissue culture system
based on magnetic nanoparticles,” was published in the journal
Tissue Engineering C.
“This paper shows just how valuable n3D’s Bio-Assembler can be in
ground-breaking research being conducted around the world,” said RBCC
CEO Patrick Brown. “As more and more high-profile cell researchers
discover this system’s potential, the market for the technology will
continue to grow exponentially.”
The Bio-Assembler’s fusion of magnetic levitation and nanoparticle
assembly technology allows it to produce accurate, 3D representations of in
vivo tissues faster and easier than any other existing tools. The
incredible device is key to RBCC’s plans to participate in the
impressive upside in store for n3D.
For more information on Rainbow BioSciences, please visit www.rainbowbiosciences.com/investors.html.
Rainbow BioSciences will develop new medical and research technology
innovations to compete alongside companies such as Bristol Myers Squibb
Co. (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories
(NYSE: ABT) and Amgen, Inc. (NASDAQ: AMGN).
About Rainbow BioSciences
Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral
Corp. (OTCBB: RBCC). The company continually seeks out new partnerships
with biotechnology developers to deliver profitable new medical
technologies and innovations. For more information on our
growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com].
For investment information and performance data on the company, please
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995: This news release contains forward-looking information within
the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements that include the words "believes," "expects,"
"anticipate" or similar expressions. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that
may cause the actual results, performance or achievements of the company
to differ materially from those expressed or implied by such
forward-looking statements. In addition, description of anyone's past
success, either financial or strategic, is no guarantee of future
success. This news release speaks as of the date first set forth above
and the company assumes no responsibility to update the information
included herein for events occurring after the date hereof.